GenFleet Therapeutics (Shanghai) (HAM:Y3L) Piotroski F-Score: 5 (As of Aug. 04, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Piotroski F-Score?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Piotroski F-Score is 5 as of Aug. 04, 2026, which is at its 10-year median of 5.00. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 1,331 Biotechnology companies, GenFleet Therapeutics (Shanghai) ranks better than 84.6% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GenFleet Therapeutics (Shanghai) has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for GenFleet Therapeutics (Shanghai)'s Piotroski F-Score or its related term are showing as below:

HAM:Y3L' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 5   Max: 5
Current: 5

During the past 3 years, the highest Piotroski F-Score of GenFleet Therapeutics (Shanghai) was 5. The lowest was 5. And the median was 5.

GenFleet Therapeutics (Shanghai)  (HAM:Y3L) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


GenFleet Therapeutics (Shanghai) Piotroski F-Score Related Terms


GenFleet Therapeutics (Shanghai) Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Piotroski F-Score Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A 5.00

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score N/A 0.00 N/A 0.00 5.00

HAM:Y3L vs VRTX, REGN, RVMD: Piotroski F-Score Comparison

For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenFleet Therapeutics (Shanghai) Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s Piotroski F-Score falls into.


HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €-217.59 Mil.
Cash Flow from Operations was €-16.45 Mil.
Revenue was €15.80 Mil.
Gross Profit was €10.14 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (79.596 + 266.22) / 2 = €172.908 Mil.
Total Assets at the begining of this year (Dec24) was €79.60 Mil.
Long-Term Debt & Capital Lease Obligation was €1.40 Mil.
Total Current Assets was €262.08 Mil.
Total Current Liabilities was €44.80 Mil.
Net Income was €-88.89 Mil.

Revenue was €13.73 Mil.
Gross Profit was €11.10 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (68.854 + 79.596) / 2 = €74.225 Mil.
Total Assets at the begining of last year (Dec23) was €68.85 Mil.
Long-Term Debt & Capital Lease Obligation was €1.83 Mil.
Total Current Assets was €74.54 Mil.
Total Current Liabilities was €327.06 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GenFleet Therapeutics (Shanghai)'s current Net Income (TTM) was -217.59. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GenFleet Therapeutics (Shanghai)'s current Cash Flow from Operations (TTM) was -16.45. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-217.59/79.596
=-2.73368008

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-88.885/68.854
=-1.29091992

GenFleet Therapeutics (Shanghai)'s return on assets of this year was -2.73368008. GenFleet Therapeutics (Shanghai)'s return on assets of last year was -1.29091992. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GenFleet Therapeutics (Shanghai)'s current Net Income (TTM) was -217.59. GenFleet Therapeutics (Shanghai)'s current Cash Flow from Operations (TTM) was -16.45. ==> -16.45 > -217.59 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=1.397/172.908
=0.00807944

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1.833/74.225
=0.02469518

GenFleet Therapeutics (Shanghai)'s gearing of this year was 0.00807944. GenFleet Therapeutics (Shanghai)'s gearing of last year was 0.02469518. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=262.084/44.801
=5.84995871

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=74.536/327.06
=0.22789702

GenFleet Therapeutics (Shanghai)'s current ratio of this year was 5.84995871. GenFleet Therapeutics (Shanghai)'s current ratio of last year was 0.22789702. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GenFleet Therapeutics (Shanghai)'s number of shares in issue this year was 295.808. GenFleet Therapeutics (Shanghai)'s number of shares in issue last year was 313.003. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=10.144/15.795
=0.64222855

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11.098/13.734
=0.80806757

GenFleet Therapeutics (Shanghai)'s gross margin of this year was 0.64222855. GenFleet Therapeutics (Shanghai)'s gross margin of last year was 0.80806757. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=15.795/79.596
=0.19843962

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=13.734/68.854
=0.19946554

GenFleet Therapeutics (Shanghai)'s asset turnover of this year was 0.19843962. GenFleet Therapeutics (Shanghai)'s asset turnover of last year was 0.19946554. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GenFleet Therapeutics (Shanghai) has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Piotroski F-Score of 5 as of Aug. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. This is near median its historical median of 5.00. Over the past decade, GenFleet Therapeutics (Shanghai)'s Piotroski F-Score has ranged from 5.00 to 5.00. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #205 out of 1331 companies in the Biotechnology industry, placing it in the top 15.4%.
Is GenFleet Therapeutics (Shanghai)'s Piotroski F-Score too high?
GenFleet Therapeutics (Shanghai)'s current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. GenFleet Therapeutics (Shanghai)'s value of 5 is 66.7% above this industry median. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #205 out of 1331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #205 out of 1331 companies for Piotroski F-Score. This places GenFleet Therapeutics (Shanghai) in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. GenFleet Therapeutics (Shanghai)'s value of 5 is 66.7% above this benchmark. Historically, GenFleet Therapeutics (Shanghai)'s own Piotroski F-Score has ranged from 5.00 to 5.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, GenFleet Therapeutics (Shanghai) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenFleet Therapeutics (Shanghai)'s current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenFleet Therapeutics (Shanghai)'s current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 66.7% above the Biotechnology industry median of 3.00. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Piotroski F-Score is 5 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price